, Tracking Stock Market Picks
Enter Symbol:
Advaxis, Inc. (ADXS) [hlAlert]

down 21.45 %

Advaxis, Inc. (ADXS) rated Buy with price target $27 by Jefferies

Posted on: Friday,  May 15, 2015  10:25 AM ET by Jefferies

Jefferies rated Buy Advaxis, Inc. (NASDAQ: ADXS) on 05/15/2015, when the stock price was $19.06. Since
then, Advaxis, Inc. has lost 21.46% as of 01/21/2016's recent price of $14.97.
If you would have followed this Jefferies's recommendation on ADXS, you would have lost 21.45% of your investment in 251 days.

Advaxis, Inc. is a development-stage biotechnology company with the focus on developing cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania (Penn), which secretes a protein sequence containing a tumor-specific antigen. This technology involves the creation of genetically engineered Listeria that stimulates the innate immune system and induces an antigen-specific immune response involving both arms of the adaptive immune system. The Company?s products in development are ADXS11-001, ADXS31-142 and ADXS31-164. The Company uses genetically engineered and attenuated Listeria monocytogenes as a therapeutic agent. The Company?s agent ADX11-001, uses a human papilloma virus (HPV) derived antigen that is present in cervical cancers.

Jefferiess' research efforts cover U.S. & International equity, high yield, convertibles, derivatives and option strategies, investment grade fixed income, post-reorganization securities, as well as special situations and quantitative research. Our team of more than 150 research professionals covers nearly 1,200 companies in more than 40 industries worldwide. Our analysts focus on identifying emerging industry themes while providing in-depth, thought provoking, objective research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/15/2015 10:25 AM Buy
19.06 27.00
as of 8/27/2015
1 Week up  2.25 %
1 Month down  -28.13 %
3 Months down  -21.08 %
1 YTD down  -21.45 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy